Study combines lapatinib with cetuximab to overcome resistance in EGFR-driven tumors, new research suggests
Thursday, May 17, 2012 - 16:30
in Health & Medicine
Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial that combines cetuximab and lapatinib.